Sign in Sign up for free

Last updated: 29 May 2018 at 8:46am EST

Harout DerSimonian Net Worth




The estimated Net Worth of Harout Der Simonian is at least $40.3 Thousand dollars as of 12 October 2016. Mr. Simonian owns over 10,000 units of Biostage stock worth over $40,300 and over the last 8 years he sold BSTG stock worth over $0. In addition, he makes $0 as Chief Scientific Officer at Biostage.

Mr. DerSimonian BSTG stock SEC Form 4 insiders trading

Harout has made over 1 trades of the Biostage stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of BSTG stock worth $9,100 on 12 October 2016.

The largest trade he's ever made was buying 10,000 units of Biostage stock on 12 October 2016 worth over $9,100. On average, Harout trades about 10,000 units every 0 days since 2016. As of 12 October 2016 he still owns at least 10,000 units of Biostage stock.

You can see the complete history of Mr. Simonian stock trades at the bottom of the page.





Harout DerSimonian biography

Harout DerSimonian is Chief Scientific Officer of the Company. He has over 20 years of experience in developing immunotherapy and cell therapy programs and was instrumental in directing the science that enabled the first FDA-approved clinical trial using autologous human stem cells for cardiac repair. Throughout his career, he has played a critical, senior role in designing and implementing therapeutic programs at leading global institutions. Dr. DerSimonian is a former assistant professor and post-doctoral fellow atHarvard Medical Schooland completed his post-doctoral training at the Dana-Faber Cancer Institute and Brigham and Women's Hospital. Dr. DerSimonian holds a Ph.D. in immunology from Tufts University and a B.A. in biology from Hartwick College.



What's Harout DerSimonian's mailing address?

Harout's mailing address filed with the SEC is C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON, MA, 01746.

Insiders trading at Biostage

Over the last 8 years, insiders at Biostage have traded over $962,849 worth of Biostage stock and bought 1,593,581 units worth $3,804,230 . The most active insiders traders include David Green, Capital Llc Dst, and Ronald J Packard. On average, Biostage executives and independent directors trade stock every 79 days with the average trade being worth of $217,604. The most recent stock trade was executed by Capital Llc Dst on 6 April 2023, trading 62,500 units of BSTG stock currently worth $375,000.



What does Biostage do?

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.



What does Biostage's logo look like?

Biostage, Inc. logo

Complete history of Mr. Simonian stock trades at Biostage

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
12 Oct 2016 BSTG Biostage, Inc. Harout Der Simonian
Chief Scientific Officer
 Buy 10,000 $0.91 $9,100
12 Oct 2016
10,000 ↗


Biostage executives and stock owners

Biostage executives and other stock owners filed with the SEC include: